Printer Friendly

CYTOTHERAPEUTICS AND MEDTRONIC TO INVESTIGATE IMPLANTS OF LIVING CELLS TO TREAT CHRONIC PAIN

CYTOTHERAPEUTICS AND MEDTRONIC TO INVESTIGATE IMPLANTS OF LIVING CELLS
 TO TREAT CHRONIC PAIN
 MINNEAPOLIS, April 28 /PRNewswire/ -- The Neurological Division of Medtronic, Inc. (NYSE: MDT) and CytoTherapeutics, Inc. (NASDAQ: CTII), announced today that they have signed a research agreement to pursue the use of encapsulated living cells for the treatment of chronic pain.
 The core technology of CytoTherapeutics consists of proprietary techniques for encapsulating living cells or tissue within semi- permeable polymer membranes. These living cells can then be inserted into the body where they receive nutrients and produce desired therapeutic biomolecules. This technology may allow the therapeutic use of implanted cells that offer advantages over traditional and biotechnology-derived medicines.
 Under the agreement, Medtronic has taken an equity position in CytoTherapeutics and will support research by its collaborators at Brown University, the University of Illinois, and at Rush Presbyterian Medical Center, Chicago, Illinois. Further financial terms were not disclosed.
 Initial investigation will involve delivery of encapsulated cells that secrete pain-disrupting biomolecules inside the spinal sheath via a specialized catheter. The goal of the project will be to develop methods of controlling pain from diseases such as cancer, which originate in the trunk or limbs, by disrupting the transmission of the pain signals to the spinal cord.
 CytoTherapeutics, Inc., of Providence, R.I., was formed in 1989 to develop cellular therapies based on membrane encapsulation technologies acquired from Brown and Washington Universities. The company's two other product candidates, NeuroCRIB and EndoCRIB, are intended to treat Parkinson's disease and diabetes, respectively.
 Medtronic, Inc., headquartered in Minneapolis, Minn., is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 4/27/92
 /CONTACT: Erika Karplus of CytoTherapeutics, 401-272-3310; or Peter Feinstein of Feinstein Partners, 617-577-8110, for CytoTherapeutics; or Dale Beumer, investor relations, 612-574-3038; or Dick Reid, public relations, 612-574-3052, both of Medtronic/
 (MDT CTII) CO: CytoTherapeutics, Inc.; Medtronic, Inc. ST: Rhode Island, Minnesota IN: MTC SU: JVN


SH -- NE001 -- 3553 04/28/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1992
Words:328
Previous Article:INVACARE REPORTS 33 PERCENT INCREASE IN FIRST QUARTER NET INCOME
Next Article:OHIO CELEBRATES NATIONAL SCIENCE & TECHNOLOGY WEEK


Related Articles
CYTOTHERAPEUTICS AND MEDTRONIC TO INVESTIGATE IMPLANTS OF LIVING CELLS TO TREAT CHRONIC PAIN
CYTOTHERAPEUTICS REPORTS FIRST QUARTER RESULTS
CYTOTHERAPEUTICS NAMES E. EDWARD BAETGE DIRECTOR OF NEUROSCIENCE
CYTOTHERAPEUTICS AND DRS. WEISS AND REYNOLDS TO INVESTIGATE USES OF NEURAL STEM CELLS TO TREAT NEURODEGENERATIVE DISORDERS
CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B
CYTOTHERAPEUTICS ANNOUNCES BROAD U.S. PATENT COVERING THE USE OF MULTIPLE CELL TYPES IN THERAPEUTIC IMPLANTS
CYTOTHERAPEUTICS ANNOUNCES FIRST QUARTER 1993 RESULTS
CYTOTHERAPEUTICS REPORTS PRELIMINARY RESULTS OF CERECRIB IMPLANT TRIAL FOR CHRONIC CANCER PAIN
CYTOTHERAPEUTICS AND MEMBRANA JOIN FORCES TO DEVELOP NEW MEMBRANES FOR ENCAPSULATED CELL THERAPY
CYTOTHERAPEUTICFS INITIATES U.S. PHASE I CLINICAL TRIAL OF PRODUCT TO TREAT CHRONIC PAIN IN CANCER PATIENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters